Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.0K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.0K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

612
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
612
Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

5.3K
Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
5.3K
Mutations01:39

Mutations

96.0K
Overview
96.0K
Glucose Transporters01:27

Glucose Transporters

28.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
28.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial.

American journal of respiratory and critical care medicine·2026
Same author

Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Hypertonic Saline or Carbocisteine in Bronchiectasis. Reply.

The New England journal of medicine·2026
Same author

The CFTR potentiator icenticaftor for treatment of bronchiectasis: an international phase 2, double-blind, randomized placebo-controlled trial.

American journal of respiratory and critical care medicine·2026
Same author

Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study.

ERJ open research·2025
Same author

Hypertonic Saline or Carbocisteine in Bronchiectasis.

The New England journal of medicine·2025
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

674

Cystic fibrosis.

J Stuart Elborn1

  • 1School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, and Belfast City Hospital, Belfast, UK.

Lancet (London, England)
|May 4, 2016
PubMed
Summary
This summary is machine-generated.

Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations, leading to mucus buildup and lung damage. New therapies targeting the underlying defect are improving lung function and patient outcomes.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.2K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Related Experiment Videos

Last Updated: Mar 21, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

674
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.2K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Area of Science:

  • Genetics
  • Pulmonology
  • Biochemistry

Background:

  • Cystic fibrosis (CF) is a prevalent, life-limiting autosomal recessive genetic disorder.
  • It stems from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, crucial for anion transport and airway mucociliary clearance.
  • CFTR dysfunction leads to mucus retention, chronic infections, and lung inflammation, impacting multiple organ systems.

Purpose of the Study:

  • To review the pathophysiology of cystic fibrosis.
  • To discuss current and emerging therapeutic strategies for CF.
  • To highlight advancements in improving quality of life and life expectancy for CF patients.

Main Methods:

  • Literature review of cystic fibrosis pathophysiology and treatment.
  • Analysis of recent clinical trial data for novel CFTR-targeting therapies.
  • Synthesis of information on multidisciplinary care models and their impact.

Main Results:

  • Traditional treatments focus on mucus clearance and infection control, improving quality of life.
  • Innovative therapies directly targeting the CFTR protein defect show significant improvements in lung function and reduced exacerbations.
  • Median life expectancy for CF patients has surpassed 40 years due to these advancements.

Conclusions:

  • CFTR-targeted therapies represent a paradigm shift, offering disease-modifying potential.
  • Ongoing development of small molecule and gene-based therapies promises further improvements for individuals with CF.
  • Multidisciplinary care remains essential for managing CF comorbidities and optimizing patient outcomes.